Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants

NCT06912295 is registered in ClinicalTrials.gov with Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT06912295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06912295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants
Lead sponsor
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 21, 2025
Completion date
October 9, 2025
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants